-
QX77 and the Logic of Chaperone-Linked Autophagy
2026-09-27
QX77 is a molecular chaperone activator for studying LAMP2A-linked autophagy and Rab11-associated trafficking. This article distinguishes chaperone-mediated autophagy from mitochondrial quality-control pathways and translates a recent BPD study into practical assay-design considerations.
-
Early-Life Adversity Weakens Innate Defense via Oxytocin
2026-09-26
In a mouse model, social deprivation during postnatal days 10–20 weakened looming-evoked defensive behavior and was associated with reduced oxytocin receptor expression in the superior colliculus. The study links this behavioral change to oxytocin signaling and reports that intranasal oxytocin ameliorated the deficit, while leaving important questions about mechanism and translation for further study.
-
Ciprofloxacin Workflows for Resistance Research
2026-09-26
Use Ciprofloxacin to connect susceptibility phenotypes with fluoroquinolone biology in carefully controlled antimicrobial resistance studies. This workflow guide shows how to handle its solubility limits and interpret results alongside carbapenemase-gene and plasmid analyses—without treating one assay as proof of another mechanism.
-
Topoisomerase I Regulates Satellite DNA Transcription
2026-09-25
This study identifies Topoisomerase I (TopI) as a regulator of RNAP II transcription from centromeric satellite DNA, linking DNA topology to chromosome-segregation biology. Its findings across human, mouse, and Drosophila systems suggest that TopI-dependent satellite transcription is evolutionarily conserved and can increase after DNA double-strand breaks.
-
Rotavirus Infection Suppresses Nrf2 Antioxidant Defense
2026-09-25
The study reports a biphasic Nrf2 response to rotavirus infection: an early, redox-sensitive increase is followed by sustained loss of Nrf2 and reduced expression of antioxidant target genes. Its intervention experiments suggest that late Nrf2 depletion is not explained simply by the canonical Keap1-Cul3 turnover route, while proteasome sensitivity and increased K48-linked ubiquitination point to a role for protein degradation.
-
Cy3 Goat Anti-Mouse IgG (H+L) Antibody Workflow
2026-09-24
Cy3 Goat Anti-Mouse IgG (H+L) Antibody detects mouse primary antibodies with a fluorescent signal for immunofluorescence, flow cytometry, and western blot workflows. It is a research-use reagent; confirm assay compatibility and optimize working conditions, and do not use it for diagnostic or clinical purposes.
-
Dimethyloxalylglycine (DMOG): Practical Lab Guide
2026-09-24
Dimethyloxalylglycine (DMOG; SKU A4506) is used to inhibit PHD enzymes and stabilize HIF-1α, providing a chemical approach to studying hypoxia-related signaling when environmental hypoxia is impractical. Use it in controlled research workflows, not for diagnostic or therapeutic purposes; select exposure conditions for the specific model and verify the response experimentally.
-
FA-PEG@ZIF8@CIP for TNBC Theranostics
2026-09-23
Li et al. developed FA-PEG@ZIF8@CIP, a folate-targeted, pH-responsive ZIF8 nanoplatform that combines ciprofloxacin delivery with ultrasound imaging and sonodynamic therapy for triple-negative breast cancer. The preclinical study links ultrasound-enhanced reactive oxygen species generation with immunogenic cell death and stronger antitumor immune responses, while also identifying important limits for clinical translation.
-
Apigenin: From HDAC Biology to Translational Strategy
2026-09-22
Apigenin connects epigenetic oncology with neuroprotection research through HDAC inhibition, apoptosis, reactive oxygen species production, and inflammatory signaling. This thought-leadership analysis translates the evidence into assay strategy, formulation guidance, and a disciplined framework for evaluating translational potential without overstating clinical readiness.
-
HMGCS2, LysoPC, and Pulmonary Fibrosis
2026-09-22
Yang et al. identify injured alveolar type II epithelial cells as a major source of accumulated lysophosphatidylcholines and connect epithelial lipid dysregulation with fibroblast activation in experimental pulmonary fibrosis. Their integrated lipidomic, transcriptomic, genetic, and animal-model data define an HMGCS2–PPARα–CPT1A/CPT2 pathway that links impaired epithelial lipid degradation to fibrotic progression.
-
Necrostatin-1: RIP1 Kinase Inhibitor Workflow
2026-09-21
Necrostatin-1 helps researchers distinguish RIP1-dependent necroptosis from other regulated cell-death programs in cell and tissue-injury models. This guide combines a practical necroptosis assay workflow with ferroptosis-aware controls inspired by recent lung cancer stem-cell research.
-
H 89 2HCl for cAMP/PKA Calcium Assays
2026-09-21
H 89 2HCl helps separate cAMP production from downstream PKA activity in calcium imaging, phosphorylation, and neurite assays. This workflow translates a hippocampal neuron study into controlled inhibitor, rescue, surface-channel, and troubleshooting experiments.
-
FITC-Concanavalin A (ConA) Conjugate Guide
2026-09-20
FITC-Concanavalin A (ConA) Conjugate provides direct fluorescent detection of accessible α-D-glucose and α-D-mannose moieties on glycoproteins and glycolipids in cell, tissue, and flow-based assays. It should be used as a carbohydrate-binding probe, not as a general protein stain or a reagent for non-carbohydrate targets.
-
Mitoxantrone Targets an ERα Interdomain Interface
2026-09-19
Wang and colleagues identify the estrogen receptor α DNA-binding domain–ligand-binding domain interface as an allosteric site targeted by mitoxantrone. Their data show that receptor binding promotes cytoplasmic redistribution and proteasomal degradation, including degradation of endocrine therapy–resistant ERα mutants, independently of mitoxantrone’s canonical DNA damage activity.
-
BML-277 for Chk2 DNA Damage Research
2026-09-18
BML-277 enables ATP-competitive Chk2 interrogation across biochemical kinase assays, irradiated T-cell models, and emerging genome-integrity studies. This guide connects practical dosing and troubleshooting with a published nuclear cGAS–Chk2 mechanism without overstating what has been experimentally validated.